Our firm is managed by a small group of executives with a track record of managing biotech businesses through the drug discovery and development process. We leverage our in-house knowledge and expertise in life sciences to provide a differentiated investment approach.
Prior to forming the General Partner, from June 2013 through October 2015, Tom managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date. Prior to Pharmacyclics, Inc., Tom spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development for HCV polymerase and protease inhibitors. Tom holds an M.B.A. from the University of California Los Angeles (2012) and a Master's degree in Organic Chemistry from the University of California Santa Barbara (2007). As a research scientist, Thomas Butler has been awarded numerous patents in the U.S. and internationally, as well as published in top academic journals such as the American Chemical Society Journal of Medicinal Chemistry.
Prior to forming Point Sur Investors, from 2008-2016, Ramses was with Pharmacyclics, Inc., a Nasdaq-listed biotech company. He began as Vice President, Finance & Administration, Corporate Secretary and acted as the Principal Financial and Accounting Officer. In that capacity he was responsible for accounting, SEC reporting, audits, and investor relations. He built and had operational responsibility for Finance, IT, HR, Legal, Facilities, Events. He later served as Executive Vice President of Corporate Affairs including Corporate Communications. Additionally, he structured and administered the international revenue for Pharmacyclics into a swiss-based subsidiary. He also actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1.0 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Prior to Pharmacyclics, Ramses worked as an asset manager and investment banker, representing European and US institutional investors, family offices and high net worth investors. He began his career at Commerzbank, Germany, where he was an investment banker and portfolio manager for institutional international accounts. Ramses earned the Diplom Kaufmann degree, with honors, in Finance and Banking from the Westfaelische Wilhelms Universitaet Muenster, Germany.
Jonathan is founder and CEO of The Trout Group, an investor relations firm in the life sciences industry. Jonathan also founded Trout Group’s sister company, Trout Capital LLC, in 2004 to assist clients in a financial advisory role. Prior to founding Trout in 1996, Jonathan was a sell-side analyst at a healthcare-focused investment bank. Before his career on Wall Street, Jonathan spent four years at DuPont Pharma in various sales and marketing positions. Jonathan holds a Bachelor of Science degree in biology and chemistry from The University of North Carolina – Chapel Hill and a Master of Business Administration degree in finance from New York University’s Stern School of Business. He also holds Series 7, 24, 79 and 63 securities licenses.
Executive Director, Investor Relations
Melinda is a serial entrepreneur with extensive marketing experience. Prior to her entrepreneurial ventures, Melinda worked in finance, first as a healthcare analyst at Moody’s Investors Services and then as a healthcare banker at Dillion, Read & Co. Inc. where she was involved in over $3 billion of financings. Melinda volunteers with Sanctuary for Families, an organization devoted to improving the lives of victims of domestic abuse and with Central Synagogue as part of a team working on elevating end of life conversations to the forefront of life. She holds a Bachelor of Arts degree in Government from Dartmouth College and a Master of Business Administration degree from Harvard Business School.
Executive Director, Investor Relations - Asia
Lei has over 20 years of cross border investment experience between the US and China. She is a founding partner of UTC Links, a M&A and boutique investment firm and is also the founder and CEO of Kerrgo who partners with Chinese and Israeli companies to invest in the life science and health care industry.
Lei was born in Shanghai and received her undergraduate degree from Fudan University with a major in World Economics. In the late 80s she came to Montana State University for her graduate studies in Applied Economics. Lei started her early career working at Cathy Investment Inc. as a project manager to organize and negotiate with different government levels on infrastructure projects built and managed by Chinese and Western joint venture companies all over China. Later she headed Human Resources and the Public Relation Departments for Bass PLC – Asia, where she restructured and reengineered multi-billion RMB ventures to ensure a smooth integration between Asian and Western businesses.
Lei is also active in the following professional affiliations:
Experts Panel Committee at China Science and Technoloy Bureau
Information Manager of VC Taskforce Silicon Valley
MADE (Montana Academy of Distinguished Entrepreneurs) appointed by Dean of University of Montana
Bioscience Alliance of Montana
Active Member of the Chinese Overseas Organization and the member of entrepreneur’s sub-committee in both US and China
Equity Research Analyst
Thanaa is a recent addition to the Point Sur Team and a Class of 2018 graduate with a major in Finance and a minor in Applied Computing from San Jose State University (SJSU). Prior to joining Point Sur full time, Thanaa spent the last 18 months as a junior analyst at the firm conducting fundamental research on innovative public biotechnology firms. Prior to the internship, she served as the Founder and CEO of the Silicon Valley Fund, a student-managed investment fund at SJSU. Where she was responsible for managing over $30,000 in capital and a team of over 20 analysts. Thanaa also served as the President of the Banking and Investment Association, and the lead student organizer of the CFO Alumni Network Event at SJSU. Thanaa also currently serves as one of the founding board members at the Spartan Angel Network, a new SJSU based accelerator investing in innovative startups founded by SJSU students and alumni.
Junior Equity Research Analyst
Shipra joined the Point Sur Team in January of 2017 as an Equity Research Junior Analyst. Prior to joining Point Sur Investors, Shipra worked as a Business Intern at Wyoming Technology Business Center (2010) while pursuing her education at University of Wyoming (UW). Shipra has taken graduate level courses in Finance at UW and has cleared CFA level I. She holds an MBA from the UW (2008). Prior to UW, she served as a Project Executive conducting techno-economic evaluation, working with International clients and suppliers, at a Consulting firm in India. She earned her Bachelors in Engineering from India.
Copyright © 2015 Point Sur Investors LLC. All rights reserved.